Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Addiction Medicine
Data on addiction medicine reported by H.A. Heit and co-researchers
March 23rd, 2008
According to recent research from the United States, "Sublingual buphrenorphine is a unique opioid medication based on its pharmacokinetics and pharmacodynamic properties." "It may be used ''on label'' as an alternative choice to methadone for the treatment of opioid addiction or ''off-label'' for the treatment of both acute and chronic pain. Because of high mu receptor affinity and resultant. blockade, it has been suggested that this might interfere with the management of moderate to severe pain in patients on opioid agonist treatment," wrote H.A. Heit and colleagues. The researchers concluded: "The following article will offer strategies and...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-23)
|
